Agree...There is a ton of under $8 calls that will be exercised on 1/19. The shorts are out of the picture like you said and I think that war of words is a waste of time. CLSN has good data the retail buyers will sell to the institutions who will carry it forward.
The over focus on Thermadox as a drug is somewhat off base. This company is all about the
delivery mechanism and the almost zero side effect profile. The technology could be worth billions and there are other companies out there that could get hurt. AMGN is my biggest candidate.
Chemo patients use a ton of Epogen.
It remains to be seen but this is a great straddle opportunity as the open interest in the puts in January and February shows. I have to believe the early speculators under $2.00 have taken their investment out and are playing on house money. But the ability of the stock to stay above $8.00 and the thrust of insider buying makes this a great spec even here.